Hexima Limited (HXL.AX)
AUD 0.01
(0.0%)
AUD 0.01
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 1 Million AUD | -69.49% |
| 2023 | 3.3 Million AUD | -78.96% |
| 2022 | 15.71 Million AUD | 43.01% |
| 2021 | 10.98 Million AUD | 86.87% |
| 2020 | 5.88 Million AUD | -3.63% |
| 2019 | 6.1 Million AUD | 277.1% |
| 2018 | 1.61 Million AUD | 8.8% |
| 2017 | 1.48 Million AUD | -78.21% |
| 2016 | 6.82 Million AUD | 10.98% |
| 2015 | 6.14 Million AUD | 0.71% |
| 2014 | 6.1 Million AUD | 4.02% |
| 2013 | 5.86 Million AUD | 0.0% |
| 2010 | 8.42 Million AUD | -41.5% |
| 2009 | 14.4 Million AUD | 118.35% |
| 2008 | 6.59 Million AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 233.56 Thousand AUD | -55.36% |
| 2024 FY | 1 Million AUD | -69.49% |
| 2024 Q4 | 541.62 Thousand AUD | 0.0% |
| 2024 Q2 | 467.12 Thousand AUD | 100.0% |
| 2023 Q1 | 1.45 Million AUD | -84.29% |
| 2023 FY | 3.3 Million AUD | -78.96% |
| 2023 Q4 | 523.19 Thousand AUD | 120.89% |
| 2023 Q3 | 236.85 Thousand AUD | -91.85% |
| 2023 Q2 | 2.9 Million AUD | 100.33% |
| 2022 FY | 15.71 Million AUD | 43.01% |
| 2022 Q3 | 4.6 Million AUD | -27.41% |
| 2022 Q4 | 9.23 Million AUD | 100.81% |
| 2022 Q2 | 6.33 Million AUD | 104.21% |
| 2022 Q1 | 3.1 Million AUD | -53.25% |
| 2021 Q4 | 6.63 Million AUD | 98.6% |
| 2021 Q1 | 2.05 Million AUD | -28.6% |
| 2021 FY | 10.98 Million AUD | 86.87% |
| 2021 Q2 | 4.2 Million AUD | 104.2% |
| 2021 Q3 | 3.34 Million AUD | -20.48% |
| 2020 Q2 | 3.05 Million AUD | 101.74% |
| 2020 Q3 | 1.32 Million AUD | -56.78% |
| 2020 Q4 | 2.88 Million AUD | 118.17% |
| 2020 FY | 5.88 Million AUD | -3.63% |
| 2020 Q1 | 1.51 Million AUD | -51.25% |
| 2019 Q3 | 1.5 Million AUD | -0.96% |
| 2019 Q1 | 1.52 Million AUD | 12.69% |
| 2019 FY | 6.1 Million AUD | 277.1% |
| 2019 Q2 | 1.52 Million AUD | 0.0% |
| 2019 Q4 | 3.1 Million AUD | 106.28% |
| 2018 Q2 | 1.52 Million AUD | -0.0% |
| 2018 Q1 | 1.52 Million AUD | 18.78% |
| 2018 FY | 1.61 Million AUD | 8.8% |
| 2018 Q4 | 1.35 Million AUD | 0.0% |
| 2018 Q3 | 1.35 Million AUD | -11.44% |
| 2017 Q2 | 1.45 Million AUD | -0.0% |
| 2017 Q4 | 1.28 Million AUD | 0.0% |
| 2017 Q3 | 1.28 Million AUD | -11.68% |
| 2017 FY | 1.48 Million AUD | -78.21% |
| 2017 Q1 | 1.45 Million AUD | -8.22% |
| 2016 Q2 | 1.6 Million AUD | -0.0% |
| 2016 FY | 6.82 Million AUD | 10.98% |
| 2016 Q1 | 1.6 Million AUD | 24.47% |
| 2016 Q4 | 1.58 Million AUD | 0.0% |
| 2016 Q3 | 1.58 Million AUD | -1.6% |
| 2015 Q2 | 1.78 Million AUD | -0.0% |
| 2015 Q1 | 1.78 Million AUD | 12.24% |
| 2015 FY | 6.14 Million AUD | 0.71% |
| 2015 Q4 | 1.29 Million AUD | 0.0% |
| 2015 Q3 | 1.29 Million AUD | -27.44% |
| 2014 Q4 | 1.58 Million AUD | 0.0% |
| 2014 Q3 | 1.58 Million AUD | 8.34% |
| 2014 Q2 | 1.46 Million AUD | -0.0% |
| 2014 Q1 | 1.46 Million AUD | 0.03% |
| 2014 FY | 6.1 Million AUD | 4.02% |
| 2013 Q2 | 1.46 Million AUD | -0.0% |
| 2013 FY | 5.86 Million AUD | 0.0% |
| 2013 Q3 | 1.46 Million AUD | -0.35% |
| 2013 Q1 | 1.46 Million AUD | 0.0% |
| 2013 Q4 | 1.46 Million AUD | 0.0% |
| 2010 FY | 8.42 Million AUD | -41.5% |
| 2009 FY | 14.4 Million AUD | 118.35% |
| 2008 FY | 6.59 Million AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AdAlta Limited | 6.76 Million AUD | 85.099% |
| Acrux Limited | 8.55 Million AUD | 88.202% |
| Race Oncology Limited | 14.77 Million AUD | 93.17% |
| Biome Australia Limited | 7.91 Million AUD | 87.249% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -67.617% |
| BTC Health Limited | -1.03 Million AUD | 197.095% |
| Chimeric Therapeutics Limited | 19.76 Million AUD | 94.897% |
| CSL Limited | 7.56 Billion AUD | 99.987% |
| Clarity Pharmaceuticals Ltd | 56.3 Million AUD | 98.208% |
| Clinuvel Pharmaceuticals Limited | 31.29 Million AUD | 96.777% |
| EZZ Life Science Holdings Limited | 39.57 Million AUD | 97.451% |
| Immutep Limited | 42.87 Million AUD | 97.647% |
| Memphasys Limited | 3.67 Million AUD | 72.576% |
| Neuren Pharmaceuticals Limited | 32.69 Million AUD | 96.915% |
| Noxopharm Limited | 7 Million AUD | 85.59% |
| Prescient Therapeutics Limited | 10.89 Million AUD | 90.744% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -237.118% |
| Starpharma Holdings Limited | 22.81 Million AUD | 95.579% |
| Tissue Repair Ltd | 6.66 Million AUD | 84.869% |
| Biotron Limited | 5.11 Million AUD | 80.262% |
| Alterity Therapeutics Limited | 23.4 Million AUD | 95.69% |
| Anatara Lifesciences Ltd | 710.21 Thousand AUD | -42.034% |
| Bio-Gene Technology Limited | 2.76 Million AUD | 63.465% |
| Zelira Therapeutics Limited | 5.94 Million AUD | 83.042% |
| Patrys Limited | 4.93 Million AUD | 79.552% |
| Orthocell Limited | 15.36 Million AUD | 93.437% |
| Imugene Limited | 135.09 Million AUD | 99.253% |
| PYC Therapeutics Limited | 60.91 Million AUD | 98.344% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -13.07% |
| Cynata Therapeutics Limited | 11.12 Million AUD | 90.931% |
| Arovella Therapeutics Limited | 10.78 Million AUD | 90.647% |
| Nanollose Limited | 12.5 Thousand AUD | -7969.354% |
| Invex Therapeutics Ltd | 3.34 Million AUD | 69.851% |
| NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | 48.67% |
| Amplia Therapeutics Limited | 8.43 Million AUD | 88.042% |
| Island Pharmaceuticals Limited | 4.12 Million AUD | 75.548% |
| Nyrada Inc. | 4.55 Million AUD | 77.855% |
| Telix Pharmaceuticals Limited | 269.26 Million AUD | 99.625% |
| Dimerix Limited | 25.64 Million AUD | 96.066% |
| PharmAust Limited | 6.65 Million AUD | 84.847% |
| AnteoTech Limited | 12.18 Million AUD | 91.723% |
| Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | 98.451% |
| Recce Pharmaceuticals Ltd | 21.68 Million AUD | 95.348% |
| Avecho Biotechnology Limited | 4.54 Million AUD | 77.807% |
| Actinogen Medical Limited | 22.77 Million AUD | 95.57% |
| Immuron Limited | 9.13 Million AUD | 88.961% |
| Argenica Therapeutics Limited | 8.26 Million AUD | 87.801% |